Basic management includes inotropic therapy, preload and afterload reduction, with diuretics, digoxin, and ACE inhibitors as first-line treatments
[3] Next-Generation Dual and Multi-Targeted Therapies on the Rise Amycretin: A Promising Dual GLP-1/Amylin Receptor Agonist Also making headlines at ADA 2025 was Amycretin (NNC0487-0111), a novel, unimolecular GLP-1 and amylin receptor agonist under development by Novo Nordisk
Findings against ethanol plus LPS-induced liver injury in mice
We cant wait to help you feel better!
As a Pennsylvania-based mobile IV therapy provider serving communities from Philadelphia to Pittsburgh, RevIVe Mobile IV Therapy meets and exceeds these standards, bringing hospital-grade care directly to your doorstep
Hoeppner MP, Lundquist A, Pirun M, Meadows JR, Zamani N, Johnson J, et al